If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A
PDUFA Target Action Date is March 31, 2023
SAN RAFAEL, Calif., Oct. 12, 2022 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S. Fo.
/PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investments that advance.
BioMarin Simplifies Organizational Structure to Increase Efficiency streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investments that advance.
/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will.